Questions, Questions for Donanemab, Lecanemab
As immunotherapies enter care, scientists explore when to stop them, how amyloid removal relates to cognitive benefit, and whether fluid markers will track both plaque and tangles responses.
ALL NEWS
6542 RESULTS
Sort By:
- Most Recent
- Most Commented
Leqembi: The Case for Long-Term Dosing
At AAIC 2024, speakers pointed to worsening biomarkers and cognition after dosing stopped, and linked the protofibrils targeted by lecanemab to neurodegeneration.
Is the ‘Atrophy’ of Immunotherapy Just the Dismantling of Plaque ‘Suburbia’?
Plaques and their surrounding cells and neurites occupy 6 percent of cortical volume. Their removal could account for shrinkage during amyloid immunotherapy.
At the Edge of Spatial Omics, Cellular Response to Amyloid Comes into View
At AAIC, scientists linked Alzheimer’s pathology to the demise of nearby neurons, and implicated plaque-adjacent glia in sparking tau pathology.
NULISA—A New Proteomic Method to Revamp Biomarker Analysis
Alzheimer’s markers are quantifiable in dried plasma, simplifying future diagnoses. With new ultrasensitive assays, hundreds of proteins could be analyzed this way.
A Finger-Prick Test for Alzheimer’s Disease?
Markers for AD can be measured in dried blood. This could greatly simplify diagnosis in far-flung areas. With new ultrasensitive assays, hundreds of proteins could be tested this way.
In Head-to-Head Testing, P-Tau217/Tau217 Comes Out on Top. By a Hair.
The percentage of tau fragments phosphorylated at amino acid 217 best pegged people with brain amyloid or tangles. The ratio’s edge over other markers is slight, though.
By Setting Standards, Experts Aim to Tame a Wild West of AD Blood Tests
An expert panel has laid out performance standards on amyloid tests. Clinical context will dictate accuracy, and online calculators might help.
A Plasma Test for Tangles?
In blood, fragments of tau containing the microtubule binding region could help diagnose dementia due to Alzheimer’s disease.
Microglial Epigenetics Hints at How ApoE Toggles Alzheimer’s Risk
When faced with amyloid, ApoE4 microglia crank up pro-inflammatory genes. ApoE2 microglia do the opposite. They quell neuroinflammation via the vitamin D receptor.
I’m Open! Exposed Enhancers Reveal Masters of Microglial Moods
At AAIC, scientists reported how specific enhancer motifs and transcription factors cooperate to shift microglia into myriad reactive states, and back again.
Implicated in ARIA: Perivascular Macrophages and Microglia
These immune cells spew free radicals and inflammatory cytokines that damage blood vessels, contributing to edema and brain bleeds.
Two New Deaths on Leqembi Highlight Need to Better Manage ARIA
These are the first deaths reported from clinical use of lecanemab. One was APOE4 homozygote; both developed severe ARIA-E and seizures.
How Presenilin Mutations Hobble γ-Secretase Predicts Onset, Progression
A study links 161 PSEN 1 mutations to age of onset and disease progression. Good news for variant calling, and for developing γ-secretase modulators.
Alzheimer's Association International Conference (AAIC) 2024
Are Alzheimer’s Blood Tests Ready for Primary Care? Living Among Us: People Whose Alzheimer’s Is Already Being Prevented First Success Stories From Alzheimer’s Secondary Prevention Trial Liraglutide Trial Was Negative Four Years Ago, Still Negative Today
Current Filters
No filters selected